These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15851780)

  • 21. Electrolyte abnormalities with zoledronic acid therapy.
    Sorscher SM
    Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
    [No Abstract]   [Full Text] [Related]  

  • 22. Zoledronic acid in metastatic bone disease: an audit based discussion.
    Akbar RA; Gosh SK; Khalil S; ul Haq SM
    J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA grants priority review for ZOMETA.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):325. PubMed ID: 12113096
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C; Swift R; Goode M; Doane L; Rogers M
    Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
    Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
    Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.
    Nagy Z
    Pathol Oncol Res; 2005; 11(3):186-7. PubMed ID: 16299941
    [No Abstract]   [Full Text] [Related]  

  • 34. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
    Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bisphosphonates in bone metastases. Fewer fractures, less pain].
    MMW Fortschr Med; 2002 Sep; 144(39):53. PubMed ID: 12422697
    [No Abstract]   [Full Text] [Related]  

  • 39. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 40. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Patel K; Brahmbhatt V; Ramu V
    Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.